- Home
- XFOR vs CVGI Comparison
XFOR vs CVGI Comparison
Compare XFOR & CVGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- CVGI
- Stock Information
- Founded
- XFOR 2014
- CVGI 2000
- Country
- XFOR United States
- CVGI United States
- Employees
- XFOR N/A
- CVGI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- CVGI Auto Parts:O.E.M.
- Sector
- XFOR Health Care
- CVGI Consumer Discretionary
- Exchange
- XFOR Nasdaq
- CVGI Nasdaq
- Market Cap
- XFOR 84.3M
- CVGI 70.3M
- IPO Year
- XFOR N/A
- CVGI 2004
- Fundamental
- Price
- XFOR $3.42
- CVGI $1.71
- Analyst Decision
- XFOR Strong Buy
- CVGI
- Analyst Count
- XFOR 3
- CVGI 0
- Target Price
- XFOR $34.17
- CVGI N/A
- AVG Volume (30 Days)
- XFOR 412.4K
- CVGI 124.3K
- Earning Date
- XFOR 11-12-2025
- CVGI 11-03-2025
- Dividend Yield
- XFOR N/A
- CVGI N/A
- EPS Growth
- XFOR N/A
- CVGI N/A
- EPS
- XFOR N/A
- CVGI N/A
- Revenue
- XFOR $32,774,000.00
- CVGI $676,815,000.00
- Revenue This Year
- XFOR $1,307.51
- CVGI N/A
- Revenue Next Year
- XFOR N/A
- CVGI $6.79
- P/E Ratio
- XFOR N/A
- CVGI N/A
- Revenue Growth
- XFOR 5721.31
- CVGI N/A
- 52 Week Low
- XFOR $1.35
- CVGI $0.81
- 52 Week High
- XFOR $26.83
- CVGI $3.31
- Technical
- Relative Strength Index (RSI)
- XFOR 52.78
- CVGI 45.83
- Support Level
- XFOR $3.35
- CVGI $1.64
- Resistance Level
- XFOR $3.63
- CVGI $1.90
- Average True Range (ATR)
- XFOR 0.31
- CVGI 0.12
- MACD
- XFOR -0.03
- CVGI -0.00
- Stochastic Oscillator
- XFOR 61.97
- CVGI 22.22
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CVGI Commercial Vehicle Group Inc.
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.